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CORRESPONDENCE Dear Editors:
We read with interest the recent international multicenter retrospective study published in Gastroenterology by Simòn-Talero et al. (1) assessing the prevalence, characteristics and outcomes of spontaneous portosystemic shunts (SPSS) in patients with cirrhosis. The authors clearly demonstrate an association of SPSS with HE, independent of liver function, and a further association with transplant-free survival in patients with MELD 6-9.
These findings are in agreement with prior, smaller studies demonstrating an association of SPSS with refractory HE (2, 3) , and accordingly shunt occlusion has been suggested as a second-line therapeutic strategy for refractory HE (4) .
Based on this, we report our retrospective single-centre experience gathering a cohort of 15 patients with available for 11 patients. Of these, 2 patients died, one due to intracerebral haemorrhage and one following acute myocardial infarction. Two patients out of 11 reported recurrent episodes of HE requiring hospital admission despite maximal therapy with lactulose and rifaximin. As noted above, adverse events from the SPSS embolization were related to portal hypertension. Thus, 3 patients developed severe ascites requiring large volume paracentesis and 1 of them also experienced variceal bleeding.
The data presented by Simòn-Talero et al demonstrate a high prevalence of SPSS (60%). In view of the increased risk of refractory HE in this population, our single-centre experience supports the efficacy of the embolization of large PSS as a procedure for the treatment of refractory HE. In keeping with other reports (4) (5) (6) , we found significant neurological improvement of patients undergoing the procedure. Unlike suggestions by other authors, we did not find an association between pre-procedural MELD score and outcome, suggesting that MELD>11 may not be an optimal method for stratification. 
